Georgina V. Long
乔治娜·朗
BSc(Med), MBBS, PhD, FRACP
Co-Medical Director, Melanoma Institute Australia; Conjoint Professor, Faculty of Medicine and Health, University of Sydney; Chair of Melanoma Medical Oncology and Translational Research澳大利亚黑色素瘤研究所联合医学主任，悉尼大学兼职教授
👥Biography 个人简介
Georgina V. Long, PhD is Co-Medical Director of Melanoma Institute Australia and Conjoint Professor at the University of Sydney, recognized globally as one of the most prolific and impactful clinical trialists in melanoma. She has led or co-led dozens of practice-changing clinical trials encompassing combination immunotherapy, adjuvant and neoadjuvant immune checkpoint blockade, and the treatment of melanoma brain metastases. Her leadership of the ABC (Anti-PD-1 Brain Collaboration) trials established that combined nivolumab and ipilimumab could achieve meaningful intracranial responses in patients with melanoma brain metastases—a population historically excluded from pivotal trials and regarded as extremely poor prognosis. Dr. Long also led the COMBI-Neo and OpACIN-neo neoadjuvant trials, demonstrating that perioperative immune checkpoint inhibition in resectable stage III disease achieves pathologic response rates exceeding 70% and substantially reduces relapse, heralding a new neoadjuvant paradigm for high-risk operable melanoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ABC Trials: Immunotherapy for Melanoma Brain Metastases
Led the Anti-PD-1 Brain Collaboration (ABC) phase II trials demonstrating that nivolumab plus ipilimumab achieved a 46% intracranial response rate in asymptomatic melanoma brain metastases without prior local therapy, establishing combination immunotherapy as the preferred systemic treatment for this previously treatment-refractory population.
Neoadjuvant Immunotherapy Paradigm — OpACIN-neo Trial
Led OpACIN-neo, demonstrating that neoadjuvant combined nivolumab plus ipilimumab (2 cycles) prior to surgery achieved pathologic response rates of 77% in stage III melanoma and that pathologic response was strongly associated with relapse-free survival, helping establish neoadjuvant immunotherapy as a new standard for resectable high-risk disease.
Adjuvant Nivolumab in Resected Stage III/IV Melanoma (CheckMate 238 Co-Leadership)
Co-led analyses from the CheckMate 238 trial establishing that adjuvant nivolumab significantly improved relapse-free survival compared with adjuvant ipilimumab in resected stage III/IV melanoma with fewer toxicities, directly shaping international adjuvant treatment guidelines.
Melanoma Biomarker and Translational Research
Directed extensive translational research characterizing tumor mutational burden, immune gene expression profiles, circulating tumor DNA (ctDNA) dynamics, and tumor microenvironment features as predictors of response and relapse in melanoma patients treated with checkpoint inhibitors, informing rational trial design and patient selection.
Representative Works 代表性著作
Anti-PD-1 Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders (ABC Trial)
Nature Medicine (2018)
ABC phase II trial demonstrating 46% intracranial response rate with nivolumab + ipilimumab in asymptomatic melanoma brain metastases, establishing effective systemic therapy for this dire population.
Neoadjuvant Ipilimumab plus Nivolumab in Resectable Stage III Melanoma
Nature Medicine (2019)
OpACIN-neo phase II trial demonstrating that split-dose neoadjuvant nivolumab plus ipilimumab achieved 77% pathologic response rates with acceptable toxicity in resectable stage III melanoma.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
New England Journal of Medicine (2017)
CheckMate 238 trial establishing nivolumab superiority over ipilimumab as adjuvant therapy in resected high-risk melanoma, with improved RFS and better tolerability.
Circulating Tumor DNA Predicts Survival in Patients with Resected High-Risk Stage II/III Melanoma
Annals of Oncology (2021)
Demonstrated that post-operative ctDNA positivity is the strongest predictor of relapse in resected melanoma, with implications for MRD-guided adjuvant therapy selection.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
关注 乔治娜·朗 的研究动态
Follow Georgina V. Long's research updates
留下邮箱，当我们发布与 Georgina V. Long（Melanoma Institute Australia / University of Sydney）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment